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Abstract
A HIC1-SIRT1-p53 circular loop in which hypermethylation in cancer 1 (HIC1) represses the transcription of SIRT1
that deacetylates and inactivates p53 thus leading to HIC1 inactivation has been identified in cell and animal mod-
els. However, the alteration and prognostic effects of HIC1-SIRT1-p53 circular loop have never been demonstrated
in human cancer patients. We examine the HIC1-SIRT1-p53 alterations in 118 lung cancer patients to define their
etiological roles in tumorigenesis. We found that patients with lung squamous cell carcinoma with low p53 acety-
lation and SIRT1 expression mostly showed low HIC1 expression, confirming deregulation of HIC1-SIRT1-p53 cir-
cular loop in the clinical model. Interestingly, the expression of deleted in breast cancer 1 (DBC1), which blocks the
interaction between SIRT1 deacetylase and p53, led to acetylated p53 in patients with lung adenocarcinoma. How-
ever, epigenetic alteration of HIC1 promoter by posttranslational modifications of histones and promoter hyper-
methylation favoring the compacted chromatin production attenuated the transcriptional induction by acetylated
p53. Importantly, lung cancer patients with altered HIC1-SIRT1-p53 circular regulation showed poor prognosis. Our
data show the first valid clinical evidence of the deregulation of HIC1-SIRT1-p53 loop in lung tumorigenesis and
prognosis. Distinct status of p53 acetylation/deacetylation and HIC1 alteration mechanism result from different
SIRT1-DBC1 control and epigenetic alteration in lung squamous cell carcinoma and lung adenocarcinoma.
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Introduction
Non–small cell lung cancer (NSCLC) represents a heterogeneous group
of cancers consisting mainly of squamous cell carcinoma (SCC) and
adenocarcinoma (AD) [1]. The 5-year survival rate has been 10% to
15% for the past two decades and differs in various tumor subtypes
[2]. Therefore, an understanding of distinct differences of the molecular
mechanisms in NSCLC subtypes may follow subtly different pathways
to tumorigenesis and is urgently needed for the development of effec-
tive personalized therapeutic modalities and diagnostic approaches.
Our genome-wide loss of heterozygosity studies showed a high de-
letion frequency at the chromosomal regions 17p13.1-13.3 in NSCLC
[3–5]. As chromosome 17p13 harbors multiple tumor suppressor
genes, such as p53 and hypermethylation in cancer 1 (HIC1), the
founding of loss of chromosomal region 17p13.1-13.3 drew our atten-
tion to the p53-HIC1-SIRT1 circular control previously proposed in
cell and animal models [6]. The HIC1 protein is a sequence-specific
transcriptional repressor [7] and a bona fide tumor suppressor [8]. One
of its repression targets is the SIRT1 NAD+-dependent deacetylase,
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which is important for chromatin silencing, gene regulation, metabo-
lism, and longevity [9]. SIRT1 modulates p53-mediated transcriptional
activation and apoptosis in cells responsive to various stresses, and
its deacetylase activity is required for these SIRT1-mediated effects
on p53 [10,11]. In addition, HIC1 is a direct transactivating target
of active acetylated p53, which binds to the p53-responsive elements
in HIC1 promoter [12,13]. A circular regulatory loop among HIC1,
SIRT1, and p53, in which HIC1 directly represses the transcription
of SIRT1 that deacetylates and thereby inactivates p53 and leads
to HIC1 inactivation, has been identified in cell and animal models
[6]. In addition, the deleted in breast cancer 1 (DBC1) protein has re-
cently been demonstrated to block the interaction between SIRT1 de-
acetylase and p53 resulting in the increase of p53 acetylation [14,15].
The above-mentioned control loops are all proposed in cell mod-
els. However, the detailed functional effects of HIC1-SIRT1-p53 cir-
cular loop have never been demonstrated in human cancer patients.
Because HIC1 is highly expressed in normal lung tissue [16] and
HIC1 and SIRT1 knockout mice show lung epithelial carcinoma and
lung defects, respectively [17,18], we now performed a comprehen-
sive analysis of HIC1, SIRT1, p53, and DBC1 alterations and their
clinical correlation study in 118 patients with NSCLC to explore
whether there is a clinical link between HIC1-SIRT1-p53 loop and
to determine how HIC1 inactivation is achieved in human NSCLC.
Materials and Methods
Subjects
Paired tumor and normal lung tissues were obtained from 118 pa-
tients with NSCLC who were recruited at the Taipei Veterans Gen-
eral Hospital between 2002 and 2004 after obtaining appropriate
institutional review board permission and informed consent from
the patients. Overall survival was calculated from the day of surgery to
the date of death or the last follow-up. The mean follow-up period
was 37.4 months (range, 1-66 months). For the methylation assay,
genomic DNA from primary lung tumor tissues was prepared using
proteinase K digestion and phenol-chloroform extraction. For the RNA
expression assay, total RNA was prepared from paired tumor lung and
normal lung tissues using Trizol reagent (Invitrogen, Carlsbad, CA).
Complementary DNA (cDNA) was synthesized using SuperScript re-
verse transcriptase (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions.
Immunohistochemical Analysis
Paraffin blocks of tumors were sectioned into 5-μm slices and then
processed using standard deparaffinization and rehydration tech-
niques. Antibodies used and their experimental conditions are sum-
marized in Table W1. Staining was scored 3, 2, 1, or 0 if more than
70%, between 36% and 70%, between 5% and 35%, or less than 5%,
respectively, of tumor cell nuclei or cytoplasm were positively stained
for SIRT1 and HIC1. The score of 1 or 0 indicated the presence of
little or no SIRT1 and HIC1. Acetylated p53 stains were recorded as
expression when more than 25% of tumor cells were positive.
Tissue Western Blot Analysis
High-quality protein for tissue Western blot analysis was extracted
from 97 tumors. Immunoblot analysis was performed using the con-
ditions described in Table W1. For HIC1 and SIRT1 proteins, tumor
cells that exhibited target protein expression less than 50% that of in-
ternal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were deemed to have an abnormal pattern. For p53, the acetylation
ratio was calculated as acetylated p53/total p53, and a ratio less than
50% was evaluated as low p53 acetylation.
Messenger RNA Expression Analysis
Reactions were carried out in a volume of 25 μl with 1 μl of
cDNA and 0.25 pmol of primers in a DNA thermal cycler. Tumor
cells that exhibited HIC1 messenger RNA (mRNA) expression,
which were normalized with GAPDH as the internal control, less
than 50% that of normal cells were deemed to have an abnormal
pattern. In addition, real-time reverse transcription–polymerase chain
reactions (RT-PCRs) were performed to measure DBC1 expression
using standard conditions in the ABI Prism 7900HR (Applied Bio-
systems, Foster City, CA). The ΔCT values, normalized relative to
β-actin mRNA levels, were calculated as relative expression levels
using the SDS software (Applied Biosystems).
Methylation-Specific PCR Assay
The primers for themethylation-specific PCR are listed in TableW2.
Positive control samples with unmethylated DNA from IMR90 nor-
mal lung cell and SssI methyltransferase-treated methylated DNA
were included for each set of PCR. The hypermethylation genes were
defined as the amplification of more M products than U products
from the tumor sample.
Lung Cancer Cell Lines
Lung cancer cell lines A549 andCL1-0weremaintained inDulbecco’s
modified Eagle’s medium and H226 cells were maintained in RPMI
1640 medium. All media were supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen,
Eugene, OR). The cells were maintained at 37°C in a humidified in-
cubator containing 5% CO2 in air.
5-Aza-2′-Deoxycytidine and Suberoylanilide Hydroxamic Acid
Treatment of Lung Cancer Cells
The A549 human lung AD cells were plated at 105 per 100-mm
culture dish on the day before treatment. The cultures were treated
for three doubling times with 2 μM 5-aza-2′-deoxycytidine (5-aza-dC)
and for 48 hours with 5 μM suberoylanilide hydroxamic acid (SAHA).
The cells were then harvested for methylation-specific PCR, RT-PCR,
and Western blot assays.
Chromatin Immunoprecipitation–PCR Assay
A549 cells were cross-linked with 1% formaldehyde for 15 min-
utes at 37°C and stopped by the addition of glycine to a final concen-
tration of 0.125 M. Sonicate lysate on ice to shear DNA to lengths
between 200 and 800 bp. Subsequent steps were performed with the
chromatin immunoprecipitation (ChIP) assay kit (Upstate Biotech-
nology, Lake Placid, NY) according to the manufacturer’s instruc-
tions. Chromatin was immunoprecipitated for 16 hours at 4°C using
antibodies described in Table W1. HIC1 and GAPDH primers used
for PCR are listed in Table W2.
Statistical Analysis
Pearson χ2 test was used to compare the frequency of HIC1,
SIRT1, DBC1, and p53 alterations in patients with NSCLC having
different clinicopathologic parameters. Type III censoring was per-
formed on subjects who were still alive at the end of the study. Sur-
vival curves were calculated according to the Kaplan-Meier method,
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and comparison was performed using the log-rank test. P ≤ .05 was
considered statistically significant.
Results
Deregulation of HIC1-SIRT1-p53 Circular Loop in Lung
SCC Patients
A total of 97 patients had tissue available for immunohistochemistry
analysis (Figure 1A) and Western blot analysis (Figure 1B) for HIC1,
SIRT1, and acetylated p53 protein expressions. The data indicated that
43.3% (42/97) and 46.4% (45/97) of tumors showed an absence or
low expression of HIC1 and SIRT1 protein, respectively. Thirty-eight
patients (39.2%) showed low acetylation of p53 protein (Table W3).
Inactivation of HIC1 leads to up-regulation of SIRT1 expression
resulting in low acetylation of p53 and thereby attenuating the func-
tion of p53. Therefore, we analyzed whether there is a clinical rele-
vance of HIC1-SIRT1-p53 circular loop in lung cancer patients.
Interestingly, a significant difference in p53 acetylation status was
found between lung SCC (57.6%, 19/33) and lung AD (30.4%,
17/56) patients (P = .012; Table 1). In stratification analyses, we
Figure 1. Protein expression and concordance analyses of acetylated p53, HIC1, and SIRT1 in patients with NSCLC. (A) Immunohisto-
chemical analysis of SIRT1, acetylated p53, and HIC1 proteins in two representative patients (no. 6 and 92) is shown. (B) Western blots
of SIRT1, acetylated p53, total p53, HIC1, and GAPDH in patient no. 6 and 92 are shown. The ratio of acetylated p53 to total p53 was
used to evaluate the p53 activity. GAPDH was used as an internal control for the analysis. According to immunohistochemistry and
Western blot analyses, patient no. 6 shows positive SIRT1 (indicated as H) and a low level of acetylated p53 and HIC1 (indicated as L),
whereas patient no. 92 shows a low level of SIRT1 and positive acetylated p53 and HIC1. (C) The χ2 analysis shows significant correlation
between low HIC1 expression and low p53 acetylation in SCC patients and (D) a correlation between low HIC1 expression and positive
SIRT1 expression in patients with lung SCC.
Table 1. Alterations of HIC1, p53, and SIRT in Relation to Tumor Types of Resected Primary NSCLC Tumors*.
Characteristics† Patients with AD (Total = 56 Cases) Patients with SCC (Total = 33 Cases)
HIC1 protein expression Positive (%) Negative (%) Positive (%) Negative (%)
25 (44.6) 31 (55.4) 23 (69.7) 10 (30.3)
SIRT1 protein expression Positive (%) Negative (%) Positive (%) Negative (%)
30 (53.6) 26 (46.4) 20 (60.6) 13 (39.4)
p53 acetylation status Acetylation (%) Low acetylation (%) Acetylation (%) Low acetylation (%)
39 (69.6) 17 (30.4) 14 (42.4) 19 (57.6).012
*P value was calculated by the Pearson χ2 test in comparison between patients with AD and SCC. Data with significance are shown as superscript values.
†A total of 97 patients were analyzed for protein expression of HIC1, p53, and SIRT1. The total number of patients shown in AD and SCC categories is less than the total number of patients analyzed
because some patients belong to other tumor subtypes of NSCLC.
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found that SCC patients with low p53 acetylation mostly showed
low HIC1 expression (Figure 1C ; P = .004). In addition, we detected
a correlation trend that low HIC1 expression was frequently detected
in patients with lung SCC with SIRT1 expression (Figure 1D; P >
.05). However, the failure to detect an association between low p53
acetylation and low HIC1 in lung AD led us to speculate whether
different mechanisms were involved in HIC1-SIRT1-p53 circular
loop in pathogenesis of lung SCC and AD patients.
Promoter Hypermethylation and Compact Chromatin of the
HIC1 Gene in Lung AD Patients and Cell Lines
To verify whether epigenetic alterations are involved in changes in
HIC1 gene expression, we carried out mRNA expression and DNA
methylation assays of HIC1 gene in 118 patients with NSCLC to ver-
ify the importance of DNA methylation during HIC1 inactivation
(Figure 2A). Methylation-specific PCR assay of tumor from 118 pa-
tients indicated that 37.3% showed HIC1 promoter hypermethylation
(Table W3). Note that HIC1 has a high level of basal methylation in
the normal lung tissue, which has been seen in previous study [19–
21]. Therefore, we used a stringent criterion to determine the meth-
ylation status in which the hypermethylation genes were defined as the
amplification of more M products than U products from the tumor
sample. Interestingly, the χ2 analysis showed that HIC1 promoter hy-
permethylation was more frequently associated with patients with lung
AD (77.5%, 31/40) than those with SCC (22.5%, 9/40; P = .052;
Figure 2B). Our data suggested that promoter hypermethylation in-
volved in HIC1 inactivation in patients with lung AD.
To investigate whether posttranslational modifications of histones
in addition to promoter hypermethylation of HIC1 locus caused the
loss of its gene expression in patients with lung AD, A549 lung AD
cell line showing a low expression of HIC1 was treated with the de-
methylating agent 5-aza-dC or the histone deacetylase inhibitor
SAHA. As shown in Figure 2C , treatment with 5-aza-dC and SAHA
both successfully restored HIC1 mRNA and protein expressions and
demethylated the promoter region of this gene in A549 cells. However,
the SIRT1 inhibitor, nicotinamide, could not restore HIC1 expression
of A549 cells, thus confirming that HIC1 is not inactivated by SIRT1-
mediated p53 deacetylation in lung AD (Figure 2D).
To further verify the posttranslational modifications of histones
and chromatin binding proteins in the HIC1 promoter of A549 cells,
we performed ChIP-PCR assay of HIC1 promoter using antibodies
against methyl CpG binding protein 2 (MeCP2) and histone H3 meth-
ylated at Lys9 (H3K9me), a repression chromatin mark. The MeCP2
protein and H3K9me repression mark were detected in the HIC1 pro-
moter, but not at GAPDH promoter in A549 cells. Failure to detect the
open chromatin mark, histone H3 acetylated at Lys9 (H3K9ac), at
HIC1 promoter in A549 cells supported the premise that HIC1 is epi-
genetically silenced as a result of both by promoter hypermethylation
and by posttranslational modifications of histones (Figure 2E). It has
been shown that SIRT1 also deacetylates histones and promotes the
formation of repression chromatin in affected regions [22]. Our
ChIP-PCR assay using an antibody against SIRT1 demonstrated that
SIRT1 bound to HIC1 promoter (Figure 2E).
DBC1 Expression Leads to Acetylation of p53 in Patients with
Lung AD
Intriguingly, we observed that loss of HIC1 expression frequently
accompanied transactively acetylated p53 in lung AD patients (Table 1).
This observation contradicts the notion that loss of HIC1 results from
failure of transcriptional activation by inactive deacetylated p53.
Recently, it has been demonstrated that DBC1 inhibits p53 deacet-
ylation by SIRT1 [14,15]. We examined the DBC1 expression by
RT-PCR in two AD and one SCC lung cancer cell lines and found
that DBC1 expressed more in AD than it did in SCC cell line (Fig-
ure 3A). Next, we detected the DBC1 expression by real-time RT-
PCR assay, and the data indicated that DBC1 expression was more
correlated with patients with lung AD (63%, 29/46) than those with
SCC (37%, 17/46; Figure 3B). In stratification analyses, we found
that DBC1 expression was frequently associated with a low HIC1
expression in patients with AD whose p53 is mostly in acetylated
form (Figure 3C ).
Correlation of the Alteration of HIC1-SIRT1-p53 Circular
Regulation with Prognosis in Patients with NSCLC
To define the prognostic effects of the alteration of HIC1-SIRT1-
p53 circular regulation in patients with NSCLC, survival curves were
estimated using the Kaplan-Meier method (Figure 4). The prognosis
assays indicated that loss of HIC1 expression tended to be associated
with poor survival in unadjusted analysis (Figure 4A). Therefore,
we further performed stratified analyses, and the data indicated that
low HIC1 expression was significantly associated with poor survival
in patients with positive SIRT1 (Figure 4B). Importantly, patients
with positive SIRT1, low acetylated p53, and low HIC1 expression
showed worse prognosis (mean survival time, 25.9 months) com-
pared with other patients (mean survival time, 43.5 months; P =
.003; Figure 4C ). In addition, we found that low acetylated p53
was associated with poor survival in late-stage patients (Figure 4D).
Discussion
In the present study, we provide the first compelling clinical evi-
dence that different p53 acetylation/deacetylation status (through
distinct SIRT1-DBC1 regulation) and HIC1 inactivation (through
distinct epigenetic control) are involved in patients with SCC and
AD lung cancer (Figure 5). In addition, this study reveals evidence
that deregulation of HIC1-SIRT1-p53 especially loss of HIC1 is a
potential prognostic biomarker in lung cancer.
High expression of SIRT1 (Figure 1) and low expression of DBC1
(Figure 3) leading to deacetylated p53 and low HIC1 expression may
be important in the pathogenesis of lung SCC as revealed from the
clinical correlations of the present study. The question whether acet-
ylation of p53 is essential or only plays a dispensable role in its ac-
tivity control remains clinically unclear [23]. Our study showed that
patients with low acetylated p53 were associated with poor survival
compared with patients with acetylated p53 (Figure 4C ). Taken to-
gether, the results of the present study suggest that p53 deacetylation
may play a role in lung tumorigenesis especially for SCC patients. In-
terestingly, our previous studies indicate that p53 mutation and p53
overexpression are more frequently found in patients with SCC than
those with AD [24,25], suggesting that p53 alteration is important in
lung SCC tumorigenesis. We had examined the DBC1 expression
level in the A549 lung AD cell line (Figure 3A). The A549 cell
showed p53 acetylation with SIRT1 expression and DBC1 expres-
sion, indicating that DBC1 expression played a role in p53 acetyla-
tion in the presence of SIRT1 deacetylase. The data confirmed our
observation that p53 was mostly in acetylated form in patients with
AD whose SIRT1 negative regulator DBC1 was expressed. Consis-
tent with our data, Zhao et al. [14] have shown that exogenous
DBC1 promotes p53 protein acetylation in H1299 lung AD cells
766 HIC1-SIRT1-p53 Loop Deregulation in Lung Cancer Tseng et al. Neoplasia Vol. 11, No. 8, 2009
Figure 2. Protein, mRNA, promoter methylation, and posttranslational modifications of histones analyses of HIC1 gene in patients with
NSCLC and in NSCLC cell lines. (A) RNA expression (upper panel) and promoter methylation status (lower panel) of HIC1 gene in rep-
resentative patients. “+,” positive mRNA expression and promoter hypermethylation as opposed to “−.” M indicates methylated reac-
tion; MW, molecular weight marker; N , the normal lung tissue; T , the tumor lung tissue; U , unmethylated reaction. IMR90 is a normal
lung cell line used as unmethylated control; SssI-treated IMR90 was used as methylated control. (B) The χ2 analysis shows that HIC1
promoter hypermethylation was significantly associated with patients with lung AD than those with SCC. (C) Effects of 5-aza-dC and
SAHA treatments on A549 lung AD cells. Methylation-specific PCR analysis shows demethylation of HIC1 gene in A549 cells after 5-aza-
dC treatment. Reverse transcription–polymerase chain reaction analyses demonstrate HIC1 mRNA re-expression in 5-aza-dC and SAHA
treated A549 cells. GAPDH was used as an internal control for expression analysis. Western blot analyses demonstrate low SIRT1 in
HIC1 re-expression of A549 cells treated with 5-aza-dC and SAHA. (D) Expression of SIRT1, acetylated p53, and total p53 proteins (upper
panel) and HIC1 RNA (lower panel) in the A549 cell line treated with SIRT1 inhibitor nicotinamide for 2, 4, and 8 hours and in the un-
treated control. The ratio between acetylated p53 and total p53 protein was increased at 4 hours after treatment. However, HIC1mRNA
expression was not increased at 2 to 8 hours after treatment of nicotinamide. IMR90 served as a positive control for HIC1 mRNA ex-
pression analysis. (E) ChIP-PCR using the MeCP2, H3K9me, H3K9ac, and SIRT1-specific antibodies for amplification of HIC1 promoter in
A549 cells. “Input,” “+,” and “−” represent data for amplification using the input DNA and immunoprecipitated DNA with and without
antibodies, respectively. A chromatin with binding of MeCP2 and SIRT1 and H3K9me modification to HIC1 promoters was observed.
GAPDH promoter served as a positive control for loose posttranslational modifications of H3K9ac analysis. (F) Overexpression of
DNMT1, DNMT3a, and DNMT3b is associated with HIC1 promoter hypermethylation.
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transfected with p53 expression vector in a dose-dependent manner.
Notably, our results show for the first time that DBC1 inactivation
enhances SIRT1-mediated deacetylation of p53, thus resulting in fur-
ther p53 deacetylation in patients with lung SCC. However, there
was no apparent correlation between SIRT1 expression and low acet-
ylated p53. This may be because p53 can be deacetylated by other
histone deacetylases such as HDAC1 [26] or because the DBC1 pro-
tein blocks the interaction between SIRT1 and p53 [14,15]. In
addition, whether some patients with lung SCC showing HIC1 pro-
moter hypermethylation was due to the methylator phenotype is
worthy of further examination.
The loss of HIC1 expression through promoter hypermethylation
and posttranslational modifications of histones resulting from the
formation of a chromatin remodeling complex including SIRT1/
MeCP2 and perhaps other histone deacetylases is important in the
pathogenesis of lung AD (Figure 2). Therefore, the binding of tran-
scription factors, RNA polymerase, and p53 to HIC1 promoter is in-
hibited, thus leading to low HIC1 mRNA expression. Low HIC1
Figure 4. Kaplan-Meier overall survival curves with respect to (A) patients in the unadjusted analysis with low HIC1 expression and (B) in
patients with positive SIRT1. (C) Patients with SIRT1-positive expression, loss of p53 acetylation, and low HIC1 expression showed
shorter survival times compared with other patients. (D) The survival curves with respect to low-acetylated p53 in late-stage patients.
Figure 3. The correlation analyses of DBC1 expression with low HIC1 and acetylated p53 expression in AD patients. (A) The DBC1
expression was detected by RT-PCR in two AD and one SCC lung cancer cell lines. (B) Four representative patients including two
AD and two SCC are shown for DBC1 mRNA expression. Low DBC1 expression was frequently associated with SCC patients indicated
by an asterisk. (C) DBC1-positive expression was frequently associated with low HIC1 expression in AD whose p53 is mostly in acety-
lated form.
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expression was associated with DNA methyltransferase (DNMT) over-
expression in patients with AD (P = .066; Figure 2F), and DNMT1
was found to bind more at the HIC1 promoter of several tumor
samples than that of matched normal lung tissues using the tissue
ChIP-PCR assay (data not shown). In addition, our study shows
that SIRT1 binds to the HIC1-methylated promoter of A549 lung
AD cell line. Consistent with our data, Pruitt et al. [27] recently dem-
onstrated that SIRT1 is involved in epigenetic silencing of tumor sup-
pressor genes, such as SFRP1, SFRP2, hMLH1, and E-cadherin genes,
in colon cancer cells in which CpG islands are densely methylated.
Interestingly, because the SIRT1 negative regulator DBC1 is expressed,
the p53 in AD is mostly in acetylated form. We observed that the
SIRT1 inhibitor, nicotinamide, enhanced p53 acetylation, consistent
with the data by Sun et al. [28] in which SIRT1 knockdown increases
p53 acetylation in A549 cell line. However, it seems that the acetylated
p53 cannot bind to the epigenetically inactivated HIC1 at the pro-
moter region to restore HIC1 expression in A549 cells (Figure 2D).
Similarly, the observation that wild-type p53 cannot overcome the
HIC1 promoter hypermethylation to activate the expression of HIC1
has been reported before [16]. Our data suggest that the epigenetic
alteration of the HIC1 promoter region is refractory to the transcrip-
tion activation by p53. It would be of interest to test the activity
of p53 on a reporter containing methylated HIC1 promoter when
DBC1 is overexpressed in A549 cells.
Interestingly, our clinical data indicated that β-catenin transactiva-
tion was frequently found in patients with low HIC1 expression
(Figure W1A), consistent with the notion that β-catenin and T-cell spe-
cific factor (TCF) are recruited to HIC1 nuclear bodies to attenuate
β-catenin/TCF–mediated transcription and that overexpression of
HIC1 suppresses the β-catenin/TCF-4–mediated transcription in cell
model [29]. We suggested that low HIC1 expression was associated
with β-catenin accumulation and β-catenin/TCF–mediated transcrip-
tional activation. Interestingly, survival data indicated that low HIC1
expression was significantly associated with poor survival in patients
with β-catenin accumulation (Figure W1B). Further mechanistic stud-
ies to investigate whether there is a link between HIC1-SIRT1-p53
loop and β-catenin accumulation in lung cancer are needed.
Survival data suggest that patients with NSCLC with inactivated
HIC1 tend to have a poor prognosis (Figure 4). It is possible that
HIC1 inactivation may put individuals at increasing risk for further
oncogenic events because HIC1 acts as a transcription repressor for
many target genes [6,7,30]. Strikingly, patients with alteration in all
three proteins including SIRT1, p53, and HIC1 experience worse
survival compared with the other groups (Figure 4C ). Clearly, any
prognostic significance in the deregulation of HIC1-SIRT1-p53 cir-
cular loop will have to be studied in the context of prospective clin-
ical trials with larger sample sizes especially in the stratified groups.
Therapeutic option targeting the restoration of HIC1 function such
as using demethylated agents and/or chromatin-remodeling drugs
may thus be favorable in a subset of patients with NSCLC with an
alteration of HIC1 expression.
In conclusion, our results provide compelling clinical evidence that
deregulation of the HIC1-SIRT1-p53 loop may be involved in lung
tumorigenesis and disease outcome. In addition, the different status
of p53 acetylation/deacetylation and HIC1 inactivation mechanisms
in patients with lung AD and SCC may result from the distinct de-
regulation of SIRT1-DBC1 and HIC1 epigenetic controls.
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Table W1. List of Antibodies and Their Reaction Conditions Used in the Present Study.
Protein Final Concentration Source
SIRT1 for Western blot analysis 1:500 Upstate, Lake Placid, NY
SIRT1 for ChIP 1:500 Upstate, Lake Placid, NY
Acetylated p53 for Western
blot analysis
1:500 Cell Signaling, Danvers, MA
Acetylated p53 for IHC 1:200 Cell Signaling, Danvers, MA
Total p53 for Western blot analysis 1:500 Santa Cruz, Delaware, CA
Total p53 for IHC 1:200 Santa Cruz, Delaware, CA
HIC1 for Western blot analysis 1:500 Cashmere Biotech, Taipei,
Taiwan (peptide sequence
as described [18])
HIC1 for IHC 1:200 Cashmere Biotech, Taipei,
Taiwan (peptide sequence
as described [18])
MeCP2 1:500 Upstate, Lake Placid, NY
H3K9me 1:500 Cell Signaling, Danvers, MA
H3K9ac 1:500 Upstate, Lake Placid, NY
DNMT1 1:500 Imgenex, San Diego, CA
GAPDH 1:2000 Novus Biologicals, Littleton, CO
IHC indicates immunohistochemistry.
Table W2. List of Primer Sequences and Their Reaction Conditions Used in the Present Study.
Gene Primer 5′ → 3′ Sequences PCR Size (bp) Tm (°C) Cycle Number
HIC1-cDNA Forward TCCGCCCTGAATGACTTTTC 164 65 40
Reverse CGATGATCACGTCGCACAAG
GAPDH Forward AATCCCATCACCATCTTCCA 588 55 25
Reverse CCTGCTTCACCACCTTCTTG
HIC1-methyl-U Forward TTGGGTTTGGTTTTTGTGTTTTG 118 65 4
Reverse CACCCTAACACCACCCTAAC 62 40
HIC1-methyl-M Forward TCGGTTTTCGCGTTTTGTTCGT 95 61 40
Reverse AACCGAAAACTATCAACCCTCG
HIC1-ChIP-PCR Forward CTGGAAACATGAGCGCCT 405 63 40
Reverse GGCGCACAGATGCTGAG
c-Myc Forward TGAAAGGCTCTCCTTGCAGC 175 58 32
Reverse GCTGGTAGAAGTTCTCCTCC
cyclin D1 Forward ATGTGTGCAGAAGGAGGTCC 199 61 32
Reverse CTTAGAGGCCACGAACATGC
MMP7 Forward TACAGTGGGAACAGGCTCAGG 181 60 32
Reverse GGCACTCCACATCTGGGCT
DBC1 Forward CAACGCACTGCCCGCAAGCTT 232 60 40
Reverse TGTTCCCGCCTATCACGCAGG
β-actin Forward GGCGGCACCACCATGTACCCT 202 58 40
Reverse AGGGGCCGGACTCGTCATACT
Table W3. Alterations of HIC1, p53, and SIRT in Total Resected Primary NSCLC Tumors An-
alyzed in the Present Study.
Characteristics Total Patients
HIC1 protein expression (total = 97 cases) Positive (%) Negative (%)
55 (56.7) 42 (43.3)
HIC1 DNA hypermethylation (total = 118 cases) Unmethylated (%) Methylated (%)
74 (62.7) 44 (37.3)
p53 acetylation status (total = 97 cases) Acetylation (%) Low acetylation (%)
59 (60.8) 38 (39.2)
SIRT1 protein expression (total = 97 cases) Positive (%) Negative (%)
52 (53.6) 45 (46.4)
Figure W1. Correlation of low HIC1 expression with β-catenin–mediated transcriptional activation and poor prognosis. (A) In patients
with low HIC1 expression, β-catenin accumulation was significantly associated with mRNA overexpression of c-myc, cyclin D1, or
MMP7. (B) Low HIC1 expression in patients with β-catenin accumulation showed poor postoperative survival.
